257 related articles for article (PubMed ID: 29110061)
21. Treatment satisfaction and persistence among postmenopausal women on osteoporosis medications: 12-month results from POSSIBLE US™.
Barrett-Connor E; Wade SW; Do TP; Satram-Hoang S; Stewart R; Gao G; Macarios D
Osteoporos Int; 2012 Feb; 23(2):733-41. PubMed ID: 21625886
[TBL] [Abstract][Full Text] [Related]
22. Association Between Gastrointestinal Events and Health Care Resource Utilization Among Patients with Osteoporosis: Analysis of a U.S. Managed Care Population.
Modi A; Gold DT; Yang X; Fan CP; Sajjan SG
J Manag Care Spec Pharm; 2015 Sep; 21(9):811-21. PubMed ID: 26308228
[TBL] [Abstract][Full Text] [Related]
23. Persistence with denosumab therapy in women affected by osteoporosis with fragility fractures: a multicenter observational real practice study in Italy.
Migliaccio S; Francomano D; Romagnoli E; Marocco C; Fornari R; Resmini G; Buffa A; Di Pietro G; Corvaglia S; Gimigliano F; Moretti A; de Sire A; Malavolta N; Lenzi A; Greco EA; Iolascon G
J Endocrinol Invest; 2017 Dec; 40(12):1321-1326. PubMed ID: 28589380
[TBL] [Abstract][Full Text] [Related]
24. Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female medicare beneficiaries.
Wang Z; Ward MM; Chan L; Bhattacharyya T
Osteoporos Int; 2014 Aug; 25(8):2109-16. PubMed ID: 24846316
[TBL] [Abstract][Full Text] [Related]
25. Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis.
Cotté FE; Fardellone P; Mercier F; Gaudin AF; Roux C
Osteoporos Int; 2010 Jan; 21(1):145-55. PubMed ID: 19459025
[TBL] [Abstract][Full Text] [Related]
26. Adherence to osteoporosis medications amongst Singaporean patients.
Cheen MH; Kong MC; Zhang RF; Tee FM; Chandran M
Osteoporos Int; 2012 Mar; 23(3):1053-60. PubMed ID: 21503813
[TBL] [Abstract][Full Text] [Related]
27. Long-term persistence and switching patterns among women using osteoporosis therapies: 24- and 36-month results from POSSIBLE US™.
Wade SW; Satram-Hoang S; Stolshek BS
Osteoporos Int; 2014 Sep; 25(9):2279-90. PubMed ID: 24942502
[TBL] [Abstract][Full Text] [Related]
28. Low persistence with oral biphosphonate treatment in postmenopausal osteoporosis.
Torre C; Guerreiro J; Mendes Z; Miranda A; Bragança F; Cristino J; Canhão H; Branco JC
Acta Reumatol Port; 2019; 44(2):114-125. PubMed ID: 31280276
[TBL] [Abstract][Full Text] [Related]
29. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
Penning-van Beest FJ; Goettsch WG; Erkens JA; Herings RM
Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
[TBL] [Abstract][Full Text] [Related]
30. Medication persistence and risk of fracture among female Medicare beneficiaries diagnosed with osteoporosis.
Liu J; Guo H; Rai P; Pinto L; Barron R
Osteoporos Int; 2018 Nov; 29(11):2409-2417. PubMed ID: 30022254
[TBL] [Abstract][Full Text] [Related]
31. Influence of patient training on persistence, compliance, and tolerability of different dosing frequency regimens of bisphosphonate therapy: An observational study in Turkish patients with postmenopausal osteoporosis.
Akarırmak Ü; Koçyiğit H; Eskiyurt N; Esmaeilzadeh S; Kuru Ö; Yalçinkaya EY; Peker Ö; Ekim AA; Özgirgin N; Çalış M; Rezvani A; Çevikol A; Eyigör S; Şendur ÖF; İrdesel J;
Acta Orthop Traumatol Turc; 2016 Aug; 50(4):415-23. PubMed ID: 27524671
[TBL] [Abstract][Full Text] [Related]
32. Association between gastrointestinal events and osteoporosis treatment initiation in women diagnosed with osteoporosis in France: a retrospective analysis.
Cortet B; Modi A; Tang J; Fan CP; Sajjan S; Weaver JP
BMC Musculoskelet Disord; 2016 Apr; 17():195. PubMed ID: 27139225
[TBL] [Abstract][Full Text] [Related]
33. Denosumab utilization among older adults in Ontario: patient characteristics, persistence with therapy, and return to therapy after an extended gap.
Ban JK; Hao BB; McCarthy L; Guilcher SJT; Cadarette SM
Osteoporos Int; 2019 Sep; 30(9):1865-1872. PubMed ID: 31317248
[TBL] [Abstract][Full Text] [Related]
34. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates.
McHorney CA; Schousboe JT; Cline RR; Weiss TW
Curr Med Res Opin; 2007 Dec; 23(12):3137-52. PubMed ID: 17988435
[TBL] [Abstract][Full Text] [Related]
35. Long-term persistence in patients with osteoporosis receiving denosumab in routine practice: 36-month non-interventional, observational study.
Borek DM; Smith RC; Gruber CN; Gruber BL
Osteoporos Int; 2019 Jul; 30(7):1455-1464. PubMed ID: 31011760
[TBL] [Abstract][Full Text] [Related]
36. Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women.
Lai PS; Chua SS; Chew YY; Chan SP
J Clin Pharm Ther; 2011 Oct; 36(5):557-67. PubMed ID: 21916908
[TBL] [Abstract][Full Text] [Related]
37. Clinical efficacy and treatment persistence of monthly minodronate for osteoporotic patients unsatisfied with, and shifted from, daily or weekly bisphosphonates: the BP-MUSASHI study.
Sakai A; Ikeda S; Okimoto N; Matsumoto H; Teshima K; Okazaki Y; Fukuda F; Arita S; Tsurukami H; Nagashima M; Yoshioka T
Osteoporos Int; 2014 Sep; 25(9):2245-53. PubMed ID: 24899103
[TBL] [Abstract][Full Text] [Related]
38. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis.
Imaz I; Zegarra P; González-Enríquez J; Rubio B; Alcazar R; Amate JM
Osteoporos Int; 2010 Nov; 21(11):1943-51. PubMed ID: 19967338
[TBL] [Abstract][Full Text] [Related]
39. A dedicated Fracture Liaison Service telephone program and use of bone turnover markers for evaluating 1-year persistence with oral bisphosphonates.
van den Berg P; van Haard PMM; van der Veer E; Geusens PP; van den Bergh JP; Schweitzer DH
Osteoporos Int; 2018 Apr; 29(4):813-824. PubMed ID: 29260291
[TBL] [Abstract][Full Text] [Related]
40. Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States.
Durden E; Pinto L; Lopez-Gonzalez L; Juneau P; Barron R
Arch Osteoporos; 2017 Dec; 12(1):22. PubMed ID: 28243883
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
